Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

2.

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.

Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S.

Oncotarget. 2014 May 15;5(9):2807-19.

3.

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.

Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B.

Invest New Drugs. 2013 Jun;31(3):696-706. doi: 10.1007/s10637-012-9865-z. Epub 2012 Aug 12.

PMID:
22886613
4.

Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.

Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, Toogood G, Coffey MC.

Mod Pathol. 2012 Oct;25(10):1333-44. doi: 10.1038/modpathol.2012.95. Epub 2012 Jun 15.

5.

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS.

Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6.

6.

The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.

Kapadia R, Coffey MC.

Methods. 2010 Dec;52(4):301-6. doi: 10.1016/j.ymeth.2010.08.011. Epub 2010 Aug 27. Review.

PMID:
20801221
7.

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE.

Mol Cancer. 2009 Jul 14;8:47. doi: 10.1186/1476-4598-8-47.

8.

Systemic reovirus therapy of metastatic cancer in immune-competent mice.

Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM, Lee PW.

Cancer Res. 2003 Jan 15;63(2):348-53.

9.

Reovirus oncolysis of human breast cancer.

Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Strong JE, Lee PW.

Hum Gene Ther. 2002 Mar 20;13(5):641-52.

PMID:
11916487
10.

Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein.

Zhao YG, Gilmore R, Leone G, Coffey MC, Weber B, Lee PW.

J Biol Chem. 2001 Aug 31;276(35):32822-7. Epub 2001 Jul 3.

11.

Reovirus therapy of tumors with activated Ras pathway.

Coffey MC, Strong JE, Forsyth PA, Lee PW.

Science. 1998 Nov 13;282(5392):1332-4.

12.

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW.

EMBO J. 1998 Jun 15;17(12):3351-62.

13.
14.

Co-translational trimerization of the reovirus cell attachment protein.

Gilmore R, Coffey MC, Leone G, McLure K, Lee PW.

EMBO J. 1996 Jun 3;15(11):2651-8.

15.

Supplemental Content

Loading ...
Support Center